This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Insulet received Food and Drug Administration clearance on ...

The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

As Insulet continues on its path to roll out its next-generation wearable insulin pump this year—and just after passing the $1 billion annual sales mark—the diabetes management company is making a ...

Insulet estimated that its total addressable market for automated insulin delivery will grow to a $9bn market value by 2028.

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...

Insulet PODD delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall. Though management ...

The FDA has cleared the first tubeless automated insulin delivery system with a smartphone app control. The FDA has cleared Insulet’s Omnipod 5 automated insulin delivery system, marking the first ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has ...

Insulet To Develop New Version Of The OmniPod Insulin Pump For Use With Humulin R U-500 Concentrated Insulin For People With Type 2 Diabetes Bedford, MA (Marketwired) - Insulet Corporation (NASDAQ: ...

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...

It seems that Insulet CorporationPODD is pulling out all the stops to strengthen its international operations. Following its news of commencing direct commercial operations in Europe, the company once ...